Russell Investments Group Ltd. Buys Shares of 68,686 Inotiv, Inc. (NASDAQ:NOTV)

Russell Investments Group Ltd. purchased a new position in shares of Inotiv, Inc. (NASDAQ:NOTV) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 68,686 shares of the company’s stock, valued at approximately $284,000. Russell Investments Group Ltd. owned 0.26% of Inotiv as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of NOTV. Vantage Point Financial LLC acquired a new position in Inotiv in the 4th quarter valued at about $1,393,000. KPP Advisory Services LLC increased its stake in Inotiv by 15.8% during the 4th quarter. KPP Advisory Services LLC now owns 275,267 shares of the company’s stock worth $1,140,000 after buying an additional 37,549 shares during the period. Geode Capital Management LLC lifted its holdings in Inotiv by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 250,895 shares of the company’s stock worth $427,000 after buying an additional 18,039 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of Inotiv by 612.5% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company’s stock worth $527,000 after acquiring an additional 109,397 shares in the last quarter. Finally, Perkins Capital Management Inc. purchased a new stake in shares of Inotiv during the fourth quarter worth $497,000. 18.17% of the stock is owned by institutional investors and hedge funds.

Inotiv Trading Up 8.5 %

NASDAQ:NOTV opened at $1.92 on Friday. The stock has a fifty day moving average price of $2.64 and a 200 day moving average price of $3.24. The company has a current ratio of 1.57, a quick ratio of 1.28 and a debt-to-equity ratio of 2.31. Inotiv, Inc. has a 12-month low of $1.15 and a 12-month high of $6.48. The firm has a market cap of $64.74 million, a PE ratio of -0.42 and a beta of 3.96.

Inotiv (NASDAQ:NOTV) last issued its quarterly earnings results on Wednesday, February 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). Inotiv had a negative return on equity of 15.41% and a negative net margin of 25.40%. Sell-side analysts anticipate that Inotiv, Inc. will post -0.79 earnings per share for the current fiscal year.

Insider Transactions at Inotiv

In related news, CEO Robert Jr. Leasure sold 73,617 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.82, for a total transaction of $281,216.94. Following the completion of the sale, the chief executive officer now owns 956,592 shares in the company, valued at $3,654,181.44. The trade was a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 108,311 shares of company stock valued at $425,330. 7.80% of the stock is currently owned by corporate insiders.

Inotiv Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.